Chardan Capital Boosts Intellia Therapeutics (NASDAQ:NTLA) Price Target to $91.00
Intellia Therapeutics (NASDAQ:NTLA – Get Free Report) had its price objective lifted by Chardan Capital from $88.00 to $91.00 in a note issued to investors on Monday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. A number of other brokerages have also issued reports on NTLA. The Goldman Sachs Group decreased their […]
18 Nov 15:42 · The Markets Daily